205 related articles for article (PubMed ID: 33147333)
1. Effect of RecA inactivation on quinolone susceptibility and the evolution of resistance in clinical isolates of Escherichia coli.
Machuca J; Recacha E; Gallego-Mesa B; Diaz-Diaz S; Rojas-Granado G; García-Duque A; Docobo-Pérez F; Blázquez J; Rodríguez-Rojas A; Pascual A; Rodríguez-Martínez JM
J Antimicrob Chemother; 2021 Jan; 76(2):338-344. PubMed ID: 33147333
[TBL] [Abstract][Full Text] [Related]
2. Quinolone Resistance Reversion by Targeting the SOS Response.
Recacha E; Machuca J; Díaz de Alba P; Ramos-Güelfo M; Docobo-Pérez F; Rodriguez-Beltrán J; Blázquez J; Pascual A; Rodríguez-Martínez JM
mBio; 2017 Oct; 8(5):. PubMed ID: 29018116
[TBL] [Abstract][Full Text] [Related]
3. Suppression of the SOS response modifies spatiotemporal evolution, post-antibiotic effect, bacterial fitness and biofilm formation in quinolone-resistant Escherichia coli.
Recacha E; Machuca J; Díaz-Díaz S; García-Duque A; Ramos-Guelfo M; Docobo-Pérez F; Blázquez J; Pascual A; Rodríguez-Martínez JM
J Antimicrob Chemother; 2019 Jan; 74(1):66-73. PubMed ID: 30329046
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Quinolone Sensitization by Targeting the
Diaz-Diaz S; Recacha E; Machuca J; García-Duque A; Docobo-Pérez F; Blázquez J; Pascual A; Rodríguez-Martínez JM
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526493
[TBL] [Abstract][Full Text] [Related]
5. Role of low-level quinolone resistance in generating tolerance in Escherichia coli under therapeutic concentrations of ciprofloxacin.
Ortiz-Padilla M; Diaz-Diaz S; Machuca J; Tejada-Gonzalez A; Recacha E; Docobo-Pérez F; Pascual A; Rodríguez-Martínez JM
J Antimicrob Chemother; 2020 Aug; 75(8):2124-2132. PubMed ID: 32427318
[TBL] [Abstract][Full Text] [Related]
6. Effect of RecA inactivation and detoxification systems on the evolution of ciprofloxacin resistance in Escherichia coli.
Diaz-Diaz S; Recacha E; García-Duque A; Docobo-Pérez F; Blázquez J; Pascual A; Rodríguez-Martínez JM
J Antimicrob Chemother; 2022 Feb; 77(3):641-645. PubMed ID: 34878138
[TBL] [Abstract][Full Text] [Related]
7. RecA inactivation as a strategy to reverse the heteroresistance phenomenon in clinical isolates of Escherichia coli.
Diaz-Diaz S; Yerbes P; Recacha E; de Gregorio-Iaria B; Pulido MR; Romero-Muñoz M; Docobo-Pérez F; Pascual A; Rodríguez-Martínez JM
Int J Antimicrob Agents; 2023 Feb; 61(2):106721. PubMed ID: 36642235
[TBL] [Abstract][Full Text] [Related]
8. Tigecycline Nonsusceptibility Occurs Exclusively in Fluoroquinolone-Resistant Escherichia coli Clinical Isolates, Including the Major Multidrug-Resistant Lineages O25b:H4-ST131-H30R and O1-ST648.
Sato T; Suzuki Y; Shiraishi T; Honda H; Shinagawa M; Yamamoto S; Ogasawara N; Takahashi H; Takahashi S; Tamura Y; Yokota SI
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855067
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Effect of SOS Response and GATC Methylome Suppression on Antibiotic Stress Survival in Escherichia coli.
Diaz-Diaz S; Recacha E; Pulido MR; Romero-Muñoz M; de Gregorio-Iaria B; Docobo-Pérez F; Pascual A; Rodríguez-Martínez JM
Antimicrob Agents Chemother; 2023 Mar; 67(3):e0139222. PubMed ID: 36802234
[TBL] [Abstract][Full Text] [Related]
10. Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli.
Machuca J; Ortiz M; Recacha E; Díaz-De-Alba P; Docobo-Perez F; Rodríguez-Martínez JM; Pascual Á
J Antimicrob Chemother; 2016 Nov; 71(11):3066-3071. PubMed ID: 27494906
[TBL] [Abstract][Full Text] [Related]
11. Novel approach for comparing the abilities of quinolones to restrict the emergence of resistant mutants during quinolone exposure.
Malik M; Hoatam G; Chavda K; Kerns RJ; Drlica K
Antimicrob Agents Chemother; 2010 Jan; 54(1):149-56. PubMed ID: 19805561
[TBL] [Abstract][Full Text] [Related]
12. Intensity and Mechanisms of Fluoroquinolone Resistance within the H30 and H30Rx Subclones of Escherichia coli Sequence Type 131 Compared with Other Fluoroquinolone-Resistant E. coli.
Johnson JR; Johnston B; Kuskowski MA; Sokurenko EV; Tchesnokova V
Antimicrob Agents Chemother; 2015 Aug; 59(8):4471-80. PubMed ID: 25987621
[TBL] [Abstract][Full Text] [Related]
13. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
[TBL] [Abstract][Full Text] [Related]
14. The Role of AcrAB-TolC Efflux Pumps on Quinolone Resistance of E. coli ST131.
Atac N; Kurt-Azap O; Dolapci I; Yesilkaya A; Ergonul O; Gonen M; Can F
Curr Microbiol; 2018 Dec; 75(12):1661-1666. PubMed ID: 30283991
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of decreased susceptibility to fluoroquinolones in avian Salmonella serovars and their mutants selected during the determination of mutant prevention concentrations.
Kehrenberg C; de Jong A; Friederichs S; Cloeckaert A; Schwarz S
J Antimicrob Chemother; 2007 May; 59(5):886-92. PubMed ID: 17369276
[TBL] [Abstract][Full Text] [Related]
16. Diverse phenotypic and genotypic characterization among clinical Klebsiella pneumoniae and Escherichia coli isolates carrying plasmid-mediated quinolone resistance determinants.
Yang J; Luo Y; Cui S; Wang W; Han L
Microb Drug Resist; 2011 Sep; 17(3):363-7. PubMed ID: 21563956
[TBL] [Abstract][Full Text] [Related]
17. Quinolone, fluoroquinolone and trimethoprim/sulfamethoxazole resistance in relation to virulence determinants and phylogenetic background among uropathogenic Escherichia coli.
Moreno E; Prats G; Sabaté M; Pérez T; Johnson JR; Andreu A
J Antimicrob Chemother; 2006 Feb; 57(2):204-11. PubMed ID: 16390858
[TBL] [Abstract][Full Text] [Related]
18. Mutant prevention concentrations of pradofloxacin for susceptible and mutant strains of Escherichia coli with reduced fluoroquinolone susceptibility.
Marcusson LL; Komp Lindgren P; Olofsson SK; Hughes D; Cars O
Int J Antimicrob Agents; 2014 Oct; 44(4):354-7. PubMed ID: 25129317
[TBL] [Abstract][Full Text] [Related]
19. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.
Linde HJ; Lehn N
J Antimicrob Chemother; 2004 Feb; 53(2):252-7. PubMed ID: 14688048
[TBL] [Abstract][Full Text] [Related]
20. Impact of co-existence of PMQR genes and QRDR mutations on fluoroquinolones resistance in Enterobacteriaceae strains isolated from community and hospital acquired UTIs.
Kotb DN; Mahdy WK; Mahmoud MS; Khairy RMM
BMC Infect Dis; 2019 Nov; 19(1):979. PubMed ID: 31752702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
